Back to companies

Sawai Pharmaceutical Co Ltd: Overview

Want to continue viewing company data?

Sign up for exclusive competitive intelligence.
Company Data Subscription $329 per month (billed Annually)
Signup to View Free Sample

Sawai Pharmaceutical Co Ltd (Sawai Pharmaceutical) manufactures, sells, imports and exports ethical drugs and proprietary drugs. The company's products include cardiovascular drugs, antihyperlipidemic agents, diabetes drugs, anticancer drugs and OTC drugs. It provides products in the form of tablets, oral dispersing tablets, capsules, granule, injection, tape, ophthalmic and nasal solution and syrup. Sawai Pharmaceutical caters to hospitals, general practitioners and dispensing pharmacies. The company has manufacturing facilities in Kanto, Kashima, Osaka, Daini, Sanda and Kyusyu. It has its presence in Sapporo, Tokyo Daiichi, Sendai, Kitakanto, Tokyo Daini, Nagoya, Osaka, Hiroshima and Fukuoka. Sawai Pharmaceutical is headquartered in Osaka, Japan.

Headquarters Japan

Address 5-2-30 Miyahara, Yodogawa-Ku, Osaka, Osaka, 532-0003


Telephone 81 6 6105 5711

No of Employees 2,414

Industry Pharmaceuticals and Healthcare

Explore premium data & analytics

300+

Marketed Drugs

Understand Sawai Pharmaceutical Co Ltd’s commercialized product portfolio to stay one step ahead of the market.

14+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Sawai Pharmaceutical Co Ltd’s relevant decision makers and contact details.

4

Clinical Trials

Determine Sawai Pharmaceutical Co Ltd go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

3

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Pipeline Drugs

Identify which of Sawai Pharmaceutical Co Ltd’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products
Cardiovascular Drugs
Antihyperlipidemic Agents
Diabetes Drugs
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2021 New Products/Services In June, the company launched eight generic drugs with 23 strengths leading its product line to comprise of 327 compounds with 808 strengths
2021 Contracts/Agreements In January, the company and Neurolief Ltd entered into an exclusive agreement to develop Relivion, a non-invasive digital medical device for migraine and depression, in Japan.
2020 New Products/Services In December, the company's subsidiary, Upsher-Smith Laboratories announced the launch of Ramelteon Tablets, 8 mg to treat insomnia characterized by difficulty with sleep onset.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Sawai Pharmaceutical Co Ltd Chugai Pharmaceutical Co Ltd COSMOS Pharmaceutical Corp Sumitomo Pharma Co Ltd ASKA Pharmaceutical Holdings Co Ltd
Headquarters Japan Japan Japan Japan Japan
City Osaka, Osaka Chuo-Ku Fukuoka-Shi Osaka-Shi Minato-Ku
State/Province - Tokyo Fukuoka Osaka Tokyo
No. of Employees 2,414 7,664 4,872 6,822 807
Entity Type Private Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Executives
Name Position Board Since Age
Mitsuo Sawai Chief Executive Officer; Chairman - Group; Representative Director Executive Board 2021 65
Kenzo Sawai Representative Director; Chief Brand Officer; Group Deputy Chairman Executive Board 2021 53
Kazuhiko Sueyoshi President; Supervisor of Corporate Strategy Executive Board 2021 64
Toru Terashima Director; Group Chief Quality & Safety Officer Executive Board 2021 62
Akira Hamada Group Chief Human Resource Officer Senior Management 2021 -
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer